Sandoz同意支付5.4亿美元解决反托拉斯诉讼,否认任何不法行为。 Sandoz agrees to pay $540 million to settle antitrust lawsuit, denying any wrongdoing.

Sandoz是非专利药品和类似生物药品的领先者,他正采取步骤解决美国反托拉斯诉讼案。 Sandoz, a leader in generic and biosimilar medicines, is taking steps to resolve a US antitrust lawsuit. 他们同意在年底前向最终付款人原告支付2.75亿美元,并为其他索赔追加2.65亿美元。 They agreed to pay $275 million to end payer plaintiffs by year-end, with an additional $265 million provision for other claims. 这一解决办法不承认错失行为,是处理反托拉斯诉讼的持续努力的一部分,桑多斯继续针对其余索赔要求进行辩护。 This settlement does not admit to wrongdoing and is part of ongoing efforts to address antitrust litigation, with Sandoz continuing to defend against remaining claims.